With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Michigan’s pension bought Palantir, Intel, and CVS Health stock, while slashing an investment in Bristol Myers in the third ...
AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...
Learn why the VictoryShares Dividend Accelerator ETF (VSDA) has underperformed its peers and why it may not be the best ...
Over 2 decades ago, the aldosterone antagonist eplerenone proved beneficial after MI complicated by left ventricular ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback